1. Home
  2. QS vs PRAX Comparison

QS vs PRAX Comparison

Compare QS & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo QuantumScape Corporation

QS

QuantumScape Corporation

HOLD

Current Price

$6.89

Market Cap

7.5B

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$299.14

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QS
PRAX
Founded
2010
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
9.6B
IPO Year
2020
2020

Fundamental Metrics

Financial Performance
Metric
QS
PRAX
Price
$6.89
$299.14
Analyst Decision
Sell
Strong Buy
Analyst Count
7
15
Target Price
$8.40
$572.13
AVG Volume (30 Days)
10.3M
309.6K
Earning Date
04-22-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
19.15
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1,827.70
$6,395.88
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.40
$26.70
52 Week High
$19.07
$354.87

Technical Indicators

Market Signals
Indicator
QS
PRAX
Relative Strength Index (RSI) 39.72 43.28
Support Level $6.43 $290.36
Resistance Level $7.28 $322.32
Average True Range (ATR) 0.31 16.93
MACD 0.12 -3.50
Stochastic Oscillator 63.38 22.92

Price Performance

Historical Comparison
QS
PRAX

About QS QuantumScape Corporation

QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: